slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 40,141-40,170
Pages 10,126
Rows per page 30
Component
40,141-40,170 of 303,780
18
The slide uses a split-panel layout to compare two different drug programs, each supported by clinical trial data (Kaplan-Meier curves and waterfall plots).AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain2 hits
19
Includes a visual representation of antibody-drug conjugate mechanism on the left.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain2 hits
20
The slide uses a comparison layout to detail two distinct drug development programs.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain2 hits
22
The slide uses a navigation bar at the top to indicate the current section (BioPharmaceuticals).AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
23
Slide uses a grid layout to present product-specific commercial updates.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
24
The slide uses a column-based layout to organize drug development programs. 'NEW' tags highlight recent additions or updates.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
25
The slide uses a three-column layout to present clinical data for three distinct drug combinations.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
26
Includes a trial design diagram for tozorakimab and indication expansion status for Saphnelo.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
28
Includes a stacked bar chart showing revenue by product (Ultomiris, Soliris, Strensiq, Other) over 2021-2022 quarters.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
29
Includes clinical trial data references and regulatory status for danicopan.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
30
The slide uses a two-column layout to contrast two distinct R&D programs.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
32
The slide uses a two-column layout to contrast short-term pipeline milestones with long-term strategic growth pillars.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction2 hits
35
The slide uses color coding to distinguish between Oncology (maroon), BioPharmaceuticals (teal), and Rare Disease (not explicitly shown in the legend but implied by the color scheme).AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
36
The slide uses a dot chart to show historical ratings and a list-based scorecard for qualitative ESG performance.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
37
Includes a stacked bar chart for quarterly revenue and a pie chart for Q4 2022 regional revenue distribution.AstraZeneca | Results Presentation Deck | 45 slides · AstraZeneca
Conference presentation Investor relations 2 hits
09
The slide uses a bar chart to show dose-dependent efficacy across three cognitive tests (HVLT, Symbol Coding, Category Fluency).ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
11
The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Golden Circle2 hits
16
The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Golden Circle2 hits
18
The slide uses a split layout: a left-hand sidebar for product summary and a right-hand side for clinical data visualization.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Golden Circle2 hits
19
The slide uses a dark sidebar for product specs and a white main area for trial design and results.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Golden Circle2 hits
29
The slide uses a split-layout: a left-hand sidebar for company/product facts and a right-hand main area for clinical data and trial design.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations Loop · Golden Circle2 hits
05
Azek | Results Presentation Deck | 16 slidesAzek | Results Presentation Deck | 16 slides · The AZEK Company
Conference presentation Investor relations Beat · Current SituationLoop · Cost Of Inaction2 hits
02
Azerion | Results Presentation Deck | 15 slidesAzerion | Results Presentation Deck | 15 slides · Azerion
Conference presentation Investor relations Beat · Attention2 hits
01
Bank of America | Investment Banking Pitch Book | 30 slidesBank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank 2 hits
03
Bank of America | Investment Banking Pitch Book | 30 slidesBank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank 2 hits
05
Includes specific financial metrics regarding SIRE's distribution yield, trading volume, and annual cash flow costs.Bank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank Beat · Situation & Context2 hits
07
The slide uses a standard 2x2-style comparison matrix structure to weigh pros and cons for two distinct parties.Bank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank Beat · Situation & Context2 hits
08
The slide outlines the strategic and procedural landscape for a potential take-private deal.Bank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank Beat · Situation & Context2 hits
10
The slide uses a combination of a stacked bar chart for issuance volume and a line chart for index performance, with a supporting data table below.Bank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank 2 hits
11
Includes an inset chart showing 2017-2022YTD trends.Bank of America | Investment Banking Pitch Book | 30 slides · BofA Securities
Consulting deck Investment bank 2 hits